Rallybio Announces Publication Of Target-Mediated Drug Disposition Modeling And Simulations Informing The RLYB212 Dosing Regimen In Pregnant Women; Dosing Regimen To Be Evaluated In Recently Initiated RLYB212 Phase 2 Clinical Trial

Benzinga · Nov 27, 2024 21:02

— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial —

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, "Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody," in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Rallybio Announces Publication Of Target-Mediated Drug Disposition Modeling And Simulations Informing The RLYB212 Dosing Regimen In Pregnant Women; Dosing Regimen To Be Evaluated In Recently Initiated RLYB212 Phase 2 Clinical Trial

Risk Disclaimer